Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2013-03-07 | AstraZeneca (UK) Cancer Research Technology (CRT) (UK) | drugs targeting cancer metabolism | R&D |
Cancer - Oncology | R&D agreement | |
2013-03-06 | Servier (France) Galapagos (Belgium) | research - R&D - development - commercialisation | Cancer - Oncology | Milestone | ||
2013-03-06 | Roche (Switzerland) BioLamina (Sweden) | laminin-based in-vitro cell culture matrices | R&D |
Regenerative medicine | R&D agreement | |
2013-03-06 | Grunenthal (Germany) Ethypharm (France) | fentanyl sublingual tablets | cancer pain | licensing |
Cancer - Oncology - CNS diseases | Licensing agreement |
2013-03-05 | DBV Technologies (France) Sanofi (France) | Active Pharmaceutical Ingredients (API) | production |
Allergic diseases - Immune diseases | Production agreement | |
2013-03-05 | Riboxx Pharmaceuticals (Germany) China National Biotec Group Company Limited (CNBG - China) | Riboxxim® | undisclosed | R&D |
Infectious diseases | R&D agreement |
2013-03-05 | AstraZeneca (UK) Targacept (USA) | alpha7 NNR modulators, alpha4beta2 NNR modulators including AZD1446 and TC-1734 | cognitive disorders, schizophrenia, Alzheimer’s disease | development |
CNS diseases - Mental diseases - Psychiatric diseases - Neurodegenerative diseases | Development agreement |
2013-03-05 | PSR Orphan Experts (The Netherlands) Agility Clinical (USA) | consulting, orphan drug development services | collaboration |
Rare diseases | Collaboration agreement | |
2013-03-04 | Addex Therapeutics (Switzerland) Viva Biotech (China) | oral small molecule adenosine 2A receptor (A2AR) positive allosteric modulators (PAMs) | R&D |
Rare diseases - Inflammatory diseases | R&D agreement | |
2013-03-01 | TikoMed (Sweden) Baylor Research Institute (USA) | IBsolvMIR | chronic pancreatitis patients receiving islet transplantation | clinical research |
Transplantation - Metabolic diseases | Clinical research agreement |
2013-02-28 | BioAlliance Pharma (France) undisclosed worldwide leader in vaccines | Lauriad® mucoadhesive technology | collaboration |
Infectious diseases | Collaboration agreement | |
2013-02-26 | Oxford Gene Technology (UK) Cancer Cytogenomics Microarray Consortium (CCMC) (UK) | whole genome, cancer-specific microarray. | licensing |
Cancer - Oncology | Licensing agreement | |
2013-02-26 | Xellia Pharmaceuticals (Norway) SINTEF Materials and Chemistry (Trondheim) the Statens Serum Institut (Denmark) | new antibiotics that target Gram-negative bacterial infections | Gram-negative bacterial infections | R&D | Infectious diseases | |
2013-02-26 | Jazz Pharmaceuticals (Ireland) Concert Pharmaceuticals (USA - MA) | deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323 | development licensing commercialisation |
CNS diseases | Licensing agreement | |
2013-02-25 | Ablynx (Belgium) Spirogen (UK) | anti-cancer drug conjugate combining Spirogen\'s proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx\'s proprietary technology platform | R&D |
Cancer - Oncology | R&D agreement | |
2013-02-25 | Xellia Pharmaceuticals (Norway) SINTEF Materials and Chemistry (Denmark) the Statens Serum Institut (Denmark) | new antibiotics | multi-drug resistant (MDR), Gram-negative bacteria infections | Infectious diseases | ||
2013-02-25 | Bone Therapeutics (Belgium) | construction of a production plant |
Construction of a production plant | |||
2013-02-22 | IntegraGen (France) Lab21 (UK) | microRNA assay for colorectal cancer diagnostic (detection of a biomarker called hsa-mir-31-3p) | colorectal cancer | R&D | Cancer - Oncology | |
2013-02-21 | UCB (Belgium) ConfometRx (USA) | novel medicines addressing unmet medical needs in Neuroscience and based on G-protein coupled receptor (GPCR) modulation | R&D | |||
2013-02-20 | Cangene (Canada) Ipsen (France) Inspiration Biopharmaceuticals (USA) | IB1001 and certain other assets including two product candidates in pre-clinical development, IB1007 (a recombinant FVIIa) and IB1008 (a recombinant FVIII). | hemophilia B | asset purchase acquisition |
Genetic diseases - Hematological diseases |